N-Acetyl-AspartylGlutamate Synthetase (RIMKLB) as a Drug Target and Biomarker

Target Name: RIMKLB

NCBI ID: G57494

RIMKLB

N-Acetyl-AspartylGlutamate Synthetase (RIMKLB) as a Drug Target and Biomarker

Introduction

N-acetyl-aspartylglutamate (NAAG) is a key enzyme in the synthesis pathway of glutamate, which is a crucial amino acid involved in various cellular processes, including neurotransmitter signaling, synaptic plasticity, and learning. The synthesis of NAAG is catalyzed by the enzyme N-acetyl-aspartylglutamate synthetase (RIMKLB), which is a protein that has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders.

RIMKLB: Structure and Function

RIMKLB is a member of the superfamily of metal-dependent enzymes known as transition metal enzymes. These enzymes use metal ions, such as zinc, cobalt, or iron, as co-factors to catalyze chemical reactions. RIMKLB is a 26-kDa protein that contains a catalytic core and a peripheral catalytic region. The catalytic core is composed of four subunits, while the peripheral catalytic region consists of a nucleotide-binding domain (NBD), a scaffold domain, and a C-terminal domain.

The NBD of RIMKLB is a nucleotide-binding domain that consists of a nucleotide-binding oligomerization domain (NBD), a protein-coding domain, and a C-terminal domain. The NBD is responsible for coordinating the binding of NAAG to the active site of the enzyme. The scaffold domain of RIMKLB is responsible for providing structural stability to the enzyme. The C-terminal domain is involved in protein-protein interactions and may contribute to the regulation of enzyme activity.

Expression and Localization

RIMKLB is expressed in various tissues, including brain, heart, and muscle. It is predominantly expressed in the brain, where it is involved in the synthesis of NAAG. RIMKLB is also expressed in other tissues, including heart and muscle, and its level of expression varies depending on the specific tissue and developmental stage.

function

RIMKLB is involved in the synthesis of NAAG, which is a key precursor of glutamate, a crucial amino acid involved in various cellular processes. NAAG is synthesized through the Shigelnik-Menten pathway, which involves the transfer of a glutamyl group from a precursor amino acid to the N-acetyl group of an aspartyl residue in the target protein. The synthesis of NAAG is a critical step in the regulation of cellular processes, including neurotransmitter signaling, synaptic plasticity, and learning.

Drug Targeting

RIMKLB is a potential drug target due to its involvement in the synthesis of NAAG, which is a crucial molecule in the regulation of cellular processes. NAAG has been implicated in various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

Dietary Modulation

The levels of RIMKLB are regulated by dietary factors, including protein intake and cell-membrane cholesterol levels. Studies have shown that adequate protein intake and cell-membrane cholesterol levels are necessary for optimal RIMKLB expression and function. Additionally, supplementation with choline, a source of N-acetyl-aspartylglutamate, has been shown to increase the levels of RIMKLB in certain tissues.

Biomarker

RIMKLB is also potential biomarker for various neurological and psychiatric disorders. The levels of RIMKLB have been shown to be affected in various neurological disorders, including Alzheimer's disease and Parkinson's disease. Additionally, studies have shown that RIMKLB levels are also affected by stress, which can contribute to the development of various psychiatric disorders.

Conclusion

In conclusion, N-acetyl-aspartylglutamate synthetase (RIMKLB) is a protein that is involved in

Protein Name: Ribosomal Modification Protein RimK Like Family Member B

Functions: Catalyzes the synthesis of beta-citryl-L-glutamate and N-acetyl-L-aspartyl-L-glutamate. Beta-citryl-L-glutamate is synthesized more efficiently than N-acetyl-L-aspartyl-L-glutamate

The "RIMKLB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RIMKLB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets